References
1. Department of Economic and Social Affairs, Population Division. World Population Ageing 2015 [electronic resource]. New York, 2015, 164 p.
2. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020, vol. 323(13), pp. 1239-1242. doi:10.1001/ jama.2020.2648.
3. Zheng Y.Y., Ma Y.T, Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020, vol. 17(5), pp. 259-260. doi:10.1038/s41569-020-0360-5.
4. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395(10223), pp. 497-506. doi:10.1016/S0140-6736(20)30183-5.
5. Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D.S., Cerini M., Farina D., Gavazzi E. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020, vol. 5(7), pp.819-824. doi:10.1001/jamacardio.2020.1096.
6. Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., Zhang Q., Wu J. Coronavirus infections and immune responses. Med Virol, 2020, vol. 92(4), pp. 424-432. doi:10.1002/jmv.25685.
7. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 2017, vol. 39(5), pp. 529-539. doi:10.1007/s00281-017-0629-x.
8. Сердечно-сосудистые события у пациентов с новой коронавирусной инфекцией COVID-19 / А.А. Плешко [и др.] // Кардиология в Беларуси. – 2021. – Т. Выпуск 4 2021. – С. 580-595. https://doi.org/10.34883/PI.2021.13.4.007
9. Suaya J.A., Stason W.B., Ades P.A. Normand S-L.T., Shepard D.S. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol, 2009, vol. 54(1), pp. 25-33.
10. WHO (2017). Dementia [electronic resource]. Available at: http://www.who.int/news-room/factsheets/detail/dementia.
11. WHO (2017). Mental health of older adults. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/mentalhealth-of-older-adults.
12. Lee P.Y., Alexander K.P., Hammill B.G., Pasquali S.K., Peterson E.D. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA, 2001, vol. 286(6), pp. 708-713.
13. Gilyarov M.Y., Zheltoukhova M.O., Konstantinova E.V., Muksinova M.D., Muradova L.S., Nesterov A.P., Udovichenko A.E. Osobennosti lecheniya ostrogo koronarnogo sindroma u pozhilyh: opyt gorodskoj klinicheskoj bolnicy №1 im. N.I. Pirogova [Treatment characteristics of acute coronary syndrome in elderly patients: practice of N.I. Pirogov city clinical hospital №1]. Ratsionalnaya farmakoterapiya v kardiologii, 2017, vol. 13(2), pp. 164-170. (in Russian).
14. Dai X., Busby-Whitehead J., Alexander K.P. Acute coronary syndrome in the older adults. J Geriatr Cardiol, 2016, vol. 13(2), pp. 101-108. doi: 10.11909/j.issn.1671-5411.2016.02.012.
15. Gale C.P., Cattle B.A., Woolston A., Woolston A., Baxter P.D., West T.H., Simms A.D., Blaxill J., Greenwood D.C., Fox K.A.A., Westet R.M. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010. Eur Heart J, 2012, vol. 33(5), pp. 630-639. doi: 10.1093/eurheartj/ehr381.
16. Bach R.G., Cannon C.P., Weintraub W.S., DiBattiste P.M., Demopoulos L.A., Anderson H.V., DeLucca P.T., Mahoney E.M., Murphy S.A., Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med, 2004, vol. 141(3), pp. 186-195.
17. Tegn N., Abdelnoor M., Aaberge L., Endresen K., Smith P., Aakhus S., Gjertsen E., Dahl-Hofseth O., Ranhoff A.H., Gullestad L., Bendz B. After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet, 2016, vol. 387(10023), pp. 1057-1065. doi: 10.1016/S0140-6736(15)01166-6.
18. Tkacheva O.N., Kotovskaya Yu.V., Feoktistova K.V., Ostapenko V.S., Osadchiy I.A., Khokhlunov S.M., Runikhina N.K., Dyplyakov D.V. Ostryj koronarnyj sindrom v starcheskom vozraste: status problemy i nereshennye voprosy [Acute coronary syndrome in elderly: current status and unresolved issues]. Kardiovaskulyarnaya terapiya i profilaktika, 2017, vol. 16(3), pp. 62-67. doi: 10.15829/1728-8800-2017-3-62-67. (in Russian).
19. Angeli F., Verdecchia P., Savonitto S., Morici N., De Servi S., Cavalliniet C. Early invasive versus selectively invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: impact of age. Catheter Cardiovasc Interv, 2014, vol. 83(5), pp. 686-701. doi: 10.1002/ccd.25307.
20. Schiele F., Meneveau N., Seronde M.F., Descotes-Genon V., Oettinger J., Ecarnot F., Bassand J.P. Reseau de Cardiologie de Franche Comte. Changes in management of elderly patients with myocardial infarction. Eur Heart J, 2009, vol. 30(8), pp. 987-894.
21. Petroni T., Zaman A., Georges J.L., Hammoudi N., Berman E., Segev A., Juliard J.M., Barthelemy O., Silvain J., Choussat R., Claude Le Feuvre 1, Gérard Helft 1 et al; Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. Heart, 2016 vol. 102: 1648-1654.
22. Armstrong P.W., Gershlick A.H., Goldstein P., Wilcox R., Danays T., Lambert Y., Sulimov V., Ortiz F.R., Ostojic M., Welsh R.C. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med, 2013, vol. 368(15), pp. 1379-1387.
23. White H.D., Braunwald E., Murphy S.A., Jacob A.J., Gotcheva N., Polonetsky L., Antman E.M. Enoxaparin vs. Unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACTTIMI 25. Eur Heart J, 2007, vol. 28(9), pp. 1066-1071.
24. Thiemann D.R., Coresh J., Shulman S.P., Gerstenblith G., Oetgen W.J., Powe N.R. Lack of Benefit for Intravenous Thrombolysis in Patients With Myocardial Infarction Who Are Older Than 75 Years. Circulation, 2000, vol. 101(19), pp. 2239-2246.
25. Клинический протокол диагностики и лечения инфаркта миокарда, нестабильной стенокардии Приложение 2 к постановлению Министерства здравоохранения Республики Беларусь 06.06. 2017 № 59, С 43-92.
26. Рекомендации ESC по ведению пациентов с острым коронарным синдромом без стойкого подъема сегмента ST 2020. Российский кардиологический журнал, 2021; 26 (3). С125-193 doi:10.15829/1560-4071-2021-4418.
27. Староверов И.И., Шахнович Р.М., Гиляров М.Ю., Комаров А.Л., Константи нова Е.В., Панченко Е.П., Явелов И.С. Евразийские клини ческие рекомендации по диагностике и лечению острого коронарного синдрома с подъемом сегмента ST (ОКСпST). Евразийский кардиологический журнал. 2020;(1):4-77. https://doi.org/10.38109/2225-1685-2020-1-4-77.
28. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, vol. 323(11), pp. 1061-1069. doi:10.1001/jama.2020.1585.
29. Husted S., James S., Becker R.C., Becker R.C., Horrow J., Katus H., Storey R.F., Cannon C.P., Heras M., Lopes R.D., Morais J., Mahaffey K.W., Bach R.G., Wojdyla D., Wallentin L. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes, 2012, vol. 5(5), pp. 680-688.
30. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus сlopidogre in рatients with аcute сoronary syndromes. N Engl J Med, 2007, vol. 357(20), pp. 2001-2015.
31. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Pfeffer M., Hohnloser S., Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet, 2006, vol. 367(9526), pp. 1903-1912. doi: 10.1016/S0140-6736(06)68845-4.
32. Lopes R.D., Rao M., Simon D.N., Thomas L., Ansell J., Fonarow G.C., Gersh B.J., Go A.S., Hylek E.M., Kowey P., Piccini J.P., Singer D.E., Chang P., Peterson E.D., Mahaffey K.W. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med, 2016, vol. 129(6), pp. 592-599. doi: 10.1016/j.amjmed.2015.12.026.
33. Capodanno D., Angiolillo D.J. Antithrombotic therapy in the elderly. J Am Coll Cardiol, 2010, vol. 56(21), pp. 1683-1692. doi: 10.1016/j.jacc.2010.04.063.
34. Tikellis C., Thomas M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept. 2012. doi:10.1155/2012/256294.
35. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, vol. 17, pp, 259-260; doi:10.1038/s41569-020-0360-5.
36. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res, 2020, vol. 81(5), pp. 537-540. doi:10.1002/ddr.21656.
37. Bozkurt B., Kovacs R., Harrington B. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail, 2020, vol. 26(5), pp. 370.
38. Catapano A.L., Graham I., de Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, vol. 37(39), pp. 2999-3058. doi: 10.1093/eurheartj/ehw272.
39. Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., Shear C. et al. Treating to New Targets (TNT) Study: does lowering lowdensity lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol, 2004, vol. 93(2), pp. 154-158.
40. 2019 Рекомендации ЕSC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска // Российский кардиологический журнал 2020; 25 (5). С. 121-193.
41. Shrestha S.K. Statin drug therapy may increase COVID-19 infection. NMJ, 2020, vol. 3(1).
42. Ryzhkova Y., Kanareykina E., Atabegashvili M., Konstantinova E., Gilyarov M. Ostryj koronarnyj sindrom u pozhilyh: osobennosti vedeniya pacientov [Acute coronary syndrome in elderly: aspects of patient management. Klinitsist]. Klinicist, 2019, vol. 13(1-2), pp. 19–26. doi: 10.17650/1818-8338-2019-13-1-2-19-26. (in Russian).
43. De Alencar Neto J.N. Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence- based Review. Cureus, 2018, vol. 10(1), pp. 2114. doi: 10.7759/cureus.2114.
44. Soukoulis V., Boden W.E., Smith S.C., O’Gara P.T. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res, 2014, vol. 114(12), pp. 1944-1958.
Поступила 03.09.2021